{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=38", "query": { "intervention": "Dose level 3", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 17830, "total_pages": 1783, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T08:11:40.726Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00739453", "title": "A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "OSI-906", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2008-10-23", "completion_date": "2012-03-03", "has_results": false, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-11-15T08:11:40.726Z", "location_count": 3, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00739453" }, { "nct_id": "NCT00601172", "title": "A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nausea and Vomiting, Chemotherapy-Induced" ], "interventions": [ { "name": "Casopitant", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 710, "start_date": "2008-03-10", "completion_date": "2009-04-13", "has_results": true, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-11-15T08:11:40.726Z", "location_count": 23, "location_summary": "Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 19 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00601172" }, { "nct_id": "NCT00868595", "title": "MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castrate Resistant Prostate Cancer (CRPC)" ], "interventions": [ { "name": "BPX-101", "type": "BIOLOGICAL" }, { "name": "AP1903", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2009-04", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2019-10-08", "last_synced_at": "2026-11-15T08:11:40.726Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00868595" }, { "nct_id": "NCT07493577", "title": "Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aneurysmal Subarachnoid Hemorrhage" ], "interventions": [ { "name": "Tirofiban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dr David Hasan, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 82, "start_date": "2026-12-05", "completion_date": "2032-05-05", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-15T08:11:40.726Z", "location_count": 2, "location_summary": "Durham, North Carolina • Houston, Texas", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07493577" }, { "nct_id": "NCT05980000", "title": "Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Head and Neck Cancer", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Carcinoma", "Metastatic Head-and-neck Squamous-cell Carcinoma", "Metastatic Head and Neck Cancer", "HNSCC" ], "interventions": [ { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2023-10-27", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-11-15T08:11:40.726Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05980000" }, { "nct_id": "NCT03922607", "title": "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "ABBV-157", "type": "DRUG" }, { "name": "Placebo for ABBV-157", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 65, "start_date": "2019-06-11", "completion_date": "2021-04-13", "has_results": false, "last_update_posted_date": "2021-05-11", "last_synced_at": "2026-11-15T08:11:40.726Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "North Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03922607" }, { "nct_id": "NCT01485731", "title": "Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Nelfinavir", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pelvic External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Pharmacokinetic Sampling", "type": "PROCEDURE" }, { "name": "Cervical Biopsy", "type": "PROCEDURE" }, { "name": "Pelvic Examination", "type": "PROCEDURE" }, { "name": "Pap Smear", "type": "PROCEDURE" }, { "name": "Audiogram", "type": "PROCEDURE" }, { "name": "Proctoscopy", "type": "PROCEDURE" }, { "name": "Cytoscopy", "type": "PROCEDURE" }, { "name": "Renal Ultrasound", "type": "PROCEDURE" }, { "name": "CT Scan", "type": "PROCEDURE" }, { "name": "Whole Body PET/CT Scan", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 8, "start_date": "2012-01", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-06-03", "last_synced_at": "2026-11-15T08:11:40.726Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485731" }, { "nct_id": "NCT03883945", "title": "A Safety and Efficacy Study to Evaluate Rosacea", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Papulopustular Rosacea" ], "interventions": [ { "name": "AIV001", "type": "DRUG" }, { "name": "Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AiViva BioPharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2021-07", "completion_date": "2022-08", "has_results": false, "last_update_posted_date": "2024-12-17", "last_synced_at": "2026-11-15T08:11:40.726Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03883945" }, { "nct_id": "NCT03423628", "title": "A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma Multiforme", "Primary Glioblastoma Multiforme", "Brain Neoplasms, Malignant", "Leptomeningeal Disease (LMD)" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "AZD1390", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 159, "start_date": "2018-04-02", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-15T08:11:40.726Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03423628" }, { "nct_id": "NCT00073736", "title": "Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "MB07133 300mg/m2/day", "type": "DRUG" }, { "name": "MB07133 600 mg/m2/day", "type": "DRUG" }, { "name": "MB07133 1200 mg/m2/day", "type": "DRUG" }, { "name": "MB07133 1800 mg/m2/day", "type": "DRUG" }, { "name": "MB07133 2400 mg/m2/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ligand Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2003-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-08-12", "last_synced_at": "2026-11-15T08:11:40.726Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073736" } ] }